重组人血管内皮抑制素注射液联合化疗治疗中晚期非小细胞肺癌的效果观察  

Effect observation of Recombinant Human Endostatin Injection combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer

作　　者：周悦乔 ZHOU Yue-qiao(Department of Oncology,Qionghai People′s Hospital,Hainan Province,Qionghai 571400,China)

机构地区：[1]海南省琼海市人民医院肿瘤内科,海南琼海571400

出　　处：《中国当代医药》2018年第8期61-63,共3页China Modern Medicine

摘　　要：目的观察重组人血管内皮抑制素注射液联合化疗治疗中晚期非小细胞肺癌的疗效。方法选取2015年10月~2016年10月我院收治的中晚期非小细胞肺癌患者60例作为本次研究对象,通过随机颜色球分组法,将所有患者分为对照组、实验组,每组30例。对照组采用常规化疗治疗,实验组采用重组人血管内皮抑制素注射液联合化疗治疗。比较两组患者的治疗效果、不同时间段(3、6、12个月)的生存率以及不良反应发生率。结果实验组患者治疗后的总有效率显著高于对照组,差异有统计学意义(P<0.05);实验组患者治疗后3个月的生存率为96.67%(29/30),对照组患者治疗后3个月的生存率为93.33%(28/30),两组比较,差异无统计学意义(P>0.05);治疗后实验组患者6个月的生存率是93.33%(28/30)、12个月的生存率是86.67%(26/30)均高于对照组的73.33%(22/30)、63.33%(19/30),差异有统计学意义(P<0.05);实验组患者的恶心呕吐发生率、血小板较少发生率均低于对照组,差异均有统计学意义(P<0.05);两组患者的肝功能损害、血红蛋白减少、白细胞减少不良反应发生率比较,差异无统计学意义(P>0.05)。结论在中晚期非小细胞肺癌患者的治疗中,重组人血管内皮抑制素注射液联合化疗治疗的效果显著,可延长患者的生存时间,降低对患者机体的损伤,值得在今后的临床中推荐应用。Objective To observe the effect of Recombinant Human Endostatin(rh-ES)Injection combined with chemotherapy on treating middle and advanced non-small cell lung cancer(NSCLC).Methods A total of 60 patients with advanced non-small cell lung cancer admitted to our hospital from October 2015 to October 2016 were selected as the research objects.All patients were divided into control group and experimental group with 30 cases in each group by random color ball grouping method.The control group was treated with conventional chemotherapy,while the experimental group was treated with Recombinant Human Endostatin Injection combined with chemotherapy.The treatment effect,survival rate at different time periods(3,6,12 months)and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the experimental group was significantly higher than that in the control group(P<0.05).The 3-month survival rate was 96.67%(29/30)in the experimental group and 93.33%(28/30)in the control group(P>0.05).The 6-month survival rate of the experimental group was 93.33%(28/30)and 12-month survival rate was 86.67%(26/30),which were higher than that of the control group 73.33%(22/30)and 63.33%(19/30),the differences were statistically significant(P<0.05).The incidence of nausea and vomiting and platelet count in the experimental group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of middle and advanced NSCLC patients,the combination of rh-ES injection and chemotherapy has a remarkable effect,which can prolong patient′s survival time and reduce the damage to the patient′s body,and is worthy of recommendation and clinical application in future.

关 键 词：重组人血管内皮抑制素注射液 化疗 中晚期 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]